Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …

Cardiovascular disease is the leading cause of death worldwide, with this trend predicted to
continue for the foreseeable future. Common disorders are associated with the stenosis or …

Background For patients with end-stage renal disease who are not candidates for fistula,
dialysis access grafts are the best option for chronic haemodialysis. However …

The goal of tissue engineering is to mitigate the critical shortage of donor organs via in vitro
fabrication of functional biological structures. Tissue engineering is one of the most …

Occlusive arterial disease, including coronary heart disease (CHD) and peripheral arterial
disease (PAD), is the main cause of death, with an annual mortality incidence predicted to …

Current clinical treatment strategies for the bypassing of small diameter (< 6 mm) blood
vessels in the management of cardiovascular disease frequently fail due to a lack of suitable …

Tissue engineered vascular grafts (TEVGs) are beginning to achieve clinical success and
hold promise as a source of grafting material when donor grafts are unsuitable or …

From microscaled capillaries to millimeter‐sized vessels, human vasculature spans multiple
scales and cell types. The convergence of bioengineering, materials science, and stem cell …

Advances in standards of care have extended the life expectancy of patients with kidney
failure. However, options for chronic vascular access for haemodialysis—an essential part of …

Vascular tissue engineering has made prodigious progress in recent years by converging
multidisciplinary approaches. Latest technological advancements foster the development of …